Biodegradable lipids for the delivery of active agents
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
1. A pharmaceutical composition comprising a lipid particle and a pharmaceutically acceptable diluent, excipient, or carrier, wherein the lipid particle comprises:
(i) a nucleic acid,
(ii) 35-65 mol % of a protonatable lipid compound,
(iii) 3-12 mol % distearoylphosphatidylcholine (DSPC),
(iv) 15-45 mol % cholesterol, and
(v) 0.5-10 mol % of 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoyl glycerol (PEG-DMG),
wherein the mol % is based on 100% total moles of lipids in the lipid particle, wherein:
the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein:
the central moiety is a nitrogen atom;
the hydrophobic tails consist of two hydrophobic tails;
each of the two hydrophobic tails independently consists of a first hydrophobic chain, an ester group, and a second hydrophobic chain, wherein the first and second hydrophobic chains are aliphatic and linked by the ester group, and the first hydrophobic chain is bonded directly to the central moiety, wherein each ester group is —C(O)O—;
each hydrophobic tail has a total carbon atom content from 17 to 26 carbon atoms; and
one of the hydrophobic tails has (a) the formula —R 12 —M 1 —R 13 , wherein R 12 is a C 4 -C 14 alkyl group, M 1 is —C(O)O—, and R 13 is a C 10 -C 20 branched alkyl group, (b) a chain length for formula —R 12 —M 1 —R 13 of 18 to 20 atoms, and (c) a total carbon atom content of 21 to 26 carbon atoms.
2. The pharmaceutical composition of claim 1 , wherein the hydrophobic tail having the formula —R 12 —M 1 —R 13 has the formula:
where R 13 is a branched C 13 -C 17 alkyl.
3. The pharmaceutical composition of claim 2 , wherein R 13 is a C 17 branched alkyl.
4. The pharmaceutical composition of claim 3 , wherein the hydrophobic tail having the formula:
has a chain length of 18 atoms.
5. The pharmaceutical composition of claim 2 , wherein R 13 is branched at the alpha position relative to the —C(O)O— group.
6. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is a vaccine.
7. The pharmaceutical composition of claim 6 , wherein the nucleic acid comprises RNA.
8. The pharmaceutical composition of claim 6 , wherein the diluent, excipient, or carrier comprises sodium acetate.
9. The pharmaceutical composition of claim 6 , wherein the PEG-DMG comprises a PEG molecule having an average molecular weight of 2,000 Da.
10. The pharmaceutical composition of claim 5 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group.
11. A method for delivering a nucleic acid, comprising administering to a subject a pharmaceutical composition comprising a lipid particle and a pharmaceutically acceptable diluent, excipient, or carrier, wherein the lipid particle comprises:
(i) a nucleic acid,
(ii) 35-65 mol % of a protonatable lipid compound,
(iii) 3-12 mol % distearoylphosphatidylcholine (DSPC),
(iv) 15-45 mol % cholesterol, and
(v) 0.5-10 mol % of 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoyl glycerol (PEG-DMG),
wherein the mol % is based on 100% total moles of lipids in the lipid particle,
wherein:
the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein:
the central moiety is a nitrogen atom;
the hydrophobic tails consist of two hydrophobic tails;
each of the two hydrophobic tails independently consists of a first hydrophobic chain, an ester group, and a second hydrophobic chain, wherein the first and second hydrophobic chains are aliphatic and linked by the ester group, and the first hydrophobic chain is bonded directly to the central moiety, wherein each ester group is —C(O)O—;
each hydrophobic tail has a total carbon atom content from 17 to 26 carbon atoms; and
one of the hydrophobic tails has (a) the formula —R 12 —M 1 —R 13 , wherein R 12 is a C 4 -C 14 alkyl group, M 1 is —C(O)O—, and R 13 is a C 10 -C 20 branched alkyl group, (b) a chain length for formula —R 12 —M 1 —R 13 of 18 to 20 atoms, and (c) a total carbon atom content of 21 to 26 carbon atoms.
12. The method of claim 11 , wherein the hydrophobic tail having the formula —R 12 —M 1 —R 13 has the formula:
wherein:
R 13 is a C 13 -C 17 branched alkyl.
13. The method of claim 12 , wherein R 13 is a C 17 branched alkyl.
14. The method of claim 13 , wherein the hydrophobic tail having the formula:
has a chain length of 18 atoms.
15. The method of claim 12 , wherein R 13 is branched at the alpha position relative to the —C(O)O— group.
16. The method of claim 15 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group.
17. The method of claim 15 , wherein the pharmaceutical composition is a vaccine.
18. The method of claim 17 , wherein the nucleic acid comprises RNA.
19. The method of claim 17 , further the diluent, excipient, or carrier comprises sodium acetate.
20. The method of claim 17 , wherein the PEG-DMG has an average molecular weight of 2,000 Da.
21. A vaccine comprising a lipid particle and a pharmaceutically acceptable diluent, excipient, or carrier, wherein the lipid particle comprises:
(i) a nucleic acid, wherein the nucleic acid comprises RNA,
(ii) 35-65 mol % of a protonatable lipid compound,
(iii) 3-12 mol % distearoylphosphatidylcholine (DSPC),
(iv) 15-45 mol % cholesterol, and
(v) 0.5-10 mol % of 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoyl glycerol (PEG-DMG),
wherein the mol % is based on 100% total moles of lipids in the lipid particle,
wherein:
the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein:
the central moiety is a nitrogen atom;
the hydrophobic tails consist of two hydrophobic tails;
each of the two hydrophobic tails independently consists of a first hydrophobic chain, an ester group, and a second hydrophobic chain, wherein the first and second hydrophobic chains are aliphatic and linked by the ester group, and the first hydrophobic chain is bonded directly to the central moiety, wherein each ester group is —C(O)O—;
each hydrophobic tail has a total carbon atom content from 17 to 26 carbon atoms; and
one of the hydrophobic tails has the formula:
wherein:
R 13 is a C 13 -C 17 branched alkyl; and
the chain length of the hydrophobic tail is from 18 to 20 atoms.
22. The vaccine of claim 21 , wherein R 13 is a C 17 branched alkyl.
23. The vaccine of claim 22 , wherein the hydrophobic tail having the formula:
has a chain length of 18 atoms.
24. The vaccine of claim 21 , wherein R 13 is branched at the alpha position relative to the —C(O)O— group.
25. The vaccine of claim 24 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group.
26. The vaccine of claim 24 , wherein the PEG-DMG comprises a PEG molecule having an average molecular weight of 2,000 Da.
27. A vaccine comprising a lipid particle and a pharmaceutically acceptable diluent, excipient, or carrier, wherein the lipid particle comprises:
(i) a nucleic acid, wherein the nucleic acid comprises RNA,
(ii) 35-65 mol % of a protonatable lipid compound,
(iii) 3-12 mol % distearoylphosphatidylcholine (DSPC),
(iv) 15-45 mol % cholesterol, and
(v) 0.5-10 mol % of a PEG-modified lipid,
wherein the mol % is based on 100% total moles of lipids in the lipid particle,
wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein:
the central moiety is a nitrogen atom;
the hydrophobic tails consist of two hydrophobic tails;
each of the two hydrophobic tails has the formula —R 12 —M 1 —R 13 , wherein:
R 12 is a C 4 -C 14 alkyl group, M 1 is —OC(O)—, and R 13 is a C 10 -C 20 branched alkyl, wherein R 13 is branched at the alpha position relative to the —OC(O)— group;
the chain length of formula —R 12 —M 1 —R 13 is 17 atoms; and
the total carbon atom content of each hydrophobic tail is 21 to 26 carbon atoms.
28. The vaccine of claim 27 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group.
29. The vaccine of claim 27 , wherein the PEG-DMG comprises a PEG molecule having an average molecular weight of 2,000 Da.